0.00Open0.00Pre Close0 Volume0 Open Interest300.00Strike Price0.00Turnover0.00%IV-44.65%PremiumNov 22, 2024Expiry Date242.00Intrinsic Value100Multiplier-7DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma--Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intuitive Surgical Stock Discussion
2. $Rocket Lab (RKLB.US)$ -- A space logistics company specializing in small satellite launches -- enabling efficient & reliable payload delivery to orbit through their Electron rocket and scalable interplanetary missions.
3. $DigitalOcean (DOCN.US)$ -- Set to become the go-...
📊⚡️📊
Gapping up
$NVIDIA (NVDA.US)$ 's shares increased by 1% after receiving a positive adjustment from Bank of America, which raised its earnings forecasts for 2025 and 2026. The financial institution highlighted Nvidia's significant market opportunity, which it now values at over $400 billion.
$Netflix (NFLX.US)$ experienced a 6.3% rise in its stock value after reporting quarterly earnings that surpassed predict...
Goldman Sachs, Morgan Stanley, Citigroup, and other top financial firms are scheduled to report earnings this week.
Investors will also get financial updates from UnitedHealth Group, Johnson & Johnson, and Intuitive Surgical, while Taiwan Semiconductor Manufacturing and Netflix also will issue earnings this week.
Retail sales, housing starts, building permits, and homebuilder confidence are also on tap this week.
Bond markets are closed for t...
Here are some popular ETFs in US!
1. Equity ETFs (Stocks)
a. SPDR S&P 500 ETF (NYSE: SPY) $SPDR S&P 500 ETF (SPY.US)$
Tracks: The S&P 500 Index, which rep...
The move surpassed Wall Street's expectations. Analysts had generally anticipated a 25 basis point cut, while the futures market had priced in a 61% probability of a 50 basis point cut and a 39% probability of a 25 basis point reduction.
Market Response to First Rate Cut
St...
In 2024, biotech stocks had a slow start, with the S&P Biotechnology Select Industry Index returning just under 4% in the first six months, compared to...
No comment yet